AAREYDRUGS.NSAAREYDRUGS.NSNSE

Revenue (LTM)

$4.7B

+20.0% YoY

Net Income (LTM)

$40M

-14.1% YoY

Free Cash Flow

$-43M

Revenue CAGR (5Y)

+9.6%

—Marginsstable

FCF($0.0B)

Profitable

Metric	Mar 21	Mar 22	Mar 23	Mar 24	Mar 25
Revenue	3,479	4,916↑41.3%	4,190↓14.8%	3,951↓5.7%	4,739↑20.0%
Gross Profit	101	195↑93.5%	115↓41.1%	132↑14.7%	91↓30.8%
Operating Income	39	118↑204.3%	135↑14.9%	28↓79.1%	3↓89.1%
Net Income	65	66↑0.6%	38↓42.5%	47↑24.2%	40↓14.1%
EBITDA	117	141↑20.6%	105↓25.7%	114↑9.2%	121↑5.7%
EPS Diluted	2.79	2.72↓2.5%	1.49↓45.2%	1.84↑23.5%	1.43↓22.3%

Metric	Mar 21	Mar 22	Mar 23	Mar 24	Mar 25
Cash & Equivalents	6	2↓69.9%	7↑267.8%	16↑125.9%	15↓7.6%
Total Current Assets	2,184	2,188↑0.2%	2,706↑23.7%	2,826↑4.4%	2,133↓24.5%
Total Assets	2,330	2,452↑5.2%	2,913↑18.8%	3,033↑4.1%	2,383↓21.4%
Total Current Liabilities	1,308	1,267↓3.1%	1,681↑32.7%	1,665↓0.9%	969↓41.8%
Total Liabilities	1,342	1,315↓2.0%	1,739↑32.2%	1,705↓1.9%	998↓41.5%
Total Equity	989	1,136↑14.9%	1,174↑3.3%	1,328↑13.1%	1,385↑4.3%
Total Debt	180	142↓21.4%	377↑166.3%	314↓16.9%	349↑11.2%
Net Debt	174	140↓19.6%	370↑164.9%	298↓19.6%	334↑12.2%

Metric	Mar 21	Mar 22	Mar 23	Mar 24	Mar 25
Operating Cash Flow	55	-45↓182.0%	-13↑71.5%	-30↓133.7%	9↑129.9%
Capital Expenditure	-29	-22↑23.5%	-10↑52.6%	-7↑30.8%	-52↓620.5%
Free Cash Flow	26	-67↓357.7%	-23↑65.3%	-37↓59.8%	-43↓16.0%
Stock-Based Comp	0	0	0	0	0
Net Change in Cash	1	-5↓411.4%	5↑212.3%	9↑72.9%	-1↓113.6%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance